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Abstract
Background: Apolipoprotein B (apoB) contains ligand-binding domain for the binding of LDL to
LDL-R site, which enables the removal of LDL from circulation. Our recent data showed that
selenium (Se) is involved in the lipid metabolism. The present study was aimed to understand the
effect of Se deficiency (0.02 ppm) and selenium supplementation (1 ppm) on apoB expression in
liver during hypercholesterolemia in male Sprague Dawley rats. Animals were fed with control and
high cholesterol diet (2%) for 1 and 2 months. ApoB levels by ELISA and protein expression by
western blot was done. Hepatic LDL receptor (LDL-R) activity (in vivo) and mRNA expression by
RT-PCR was monitored.
Results: In selenium deficiency and on high cholesterol diet (HCD) feeding apoB levels increased
and LDL-R expression decreased significantly after 2 months. On 1 ppm selenium supplementation
apoB expression significantly decreased and LDL-R expression increased after 2 months. But after
one month of treatment there was no significant change observed in apoB and LDL-R expression.
Conclusion: So the present study demonstrates that Se deficiency leads to up regulation of apoB
expression during experimental hypercholesterolemia. Selenium supplementation upto 1 ppm
leads to downregulation of apoB expression. Further, this study will highlight the nutritional value
of Se supplementation in lipid metabolism.
Background
The interaction between LDL and LDL receptor has a
major role in determining plasma cholesterol levels [1,2]
and apolipoprotein B (apoB) has the central role in this
ligand-receptor interaction. Mutations in the apoB gene
result in accumulation of LDL in circulation [3,4]. How-
ever, most of the studies suggested that one molecule of
apoB exists per lipoproteinparticle, thus the quantity of
apoB in fasting plasma predicts the number of LDL and
VLDL particles [5,6]. Therefore, plasma apoB levels maybe
a better assay of the concentration of atherogenic lipopro-
teinparticles than total or LDL cholesterol levels [7]. Fur-
thermore, a cross-sectional study in patients who had
coronary arterybypass graft surgery determined that apoB
concentration wasa better discriminator than LDL choles-
terol concentration inpredicting recurrent atherosclerotic
disease in bypass grafts10 years after surgery [8].
Abnormalities in the apoB metabolism are responsible for
the generation of hypercholesterolemia and increased risk
of coronary heart disease [9]. Homma [10] reported a pos-
itive correlation between serum apoB levels and athero-
sclerotic conditions. Abraham et al. [11] have found a
significantly increased production of apoB levels in cul-
Published: 05 November 2005
Lipids in Health and Disease 2005, 4:28 doi:10.1186/1476-511X-4-28
Received: 17 October 2005
Accepted: 05 November 2005
This article is available from: http://www.lipidworld.com/content/4/1/28
© 2005 Dhingra and Bansal; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Lipids in Health and Disease 2005, 4:28 http://www.lipidworld.com/content/4/1/28
Page 2 of 13
(page number not for citation purposes)
tured hepatocytes isolated from rats fed with atherogenic
diet. Incubation of hepatocytes isolated from normal rats
with added cholesterol resulted in an increased synthesis
and secretion of apoB levels [12].
Several studies suggested that T3 is directly involved in the
regulation of LDL-R and apoB expression [13,14]. Nor-
mally thyroid is the unique source of T4, but it secretes
only 20% of the whole T3 in the body. Major amount of
T3 is produced from T4 by 5'-deiodination in peripheral
tissues [15]. This reaction is catalyzed by type-I 5'-
iodothyronine deiodinase (5'-DI). Type-1 5'-iodothyro-
nine deiodinase being a selenoprotein its activity
decreases during selenium (Se) deficiency [16,17]. Hence
during Se deficiency, T3 can not be produced in any quan-
tity. This makes the role of Se important for lipid metabo-
lism, since T3 is known to regulate the LDL-R level, which
is further responsible for the maintenance of plasma cho-
lesterol level. Wojcicki et al. [18] reported the protective
role of Se against atherosclerosis.
Hence in view of all the above stated findings, present
study is aimed to understand the effect of Se status on
apoB levels under experimental hypercholesterolemic
conditions in SD male rats. To the best of our knowledge,
so far no other study has been reported linking Se status
with apoB expression during hypercholesterolemia.
Results
Selenium levels
Se levels in the serum and liver decreased significantly (p
< 0.001) in Se deficient groups (Ia and Ib) and increased
in 1 ppm Se supplemented diet fed groups (IIIa and IIIb)
in comparison to respective adequate groups (IIa and IIb).
Significant decrease (p < 0.001) in the level was observed
in HCD fed groups as compared to respective controls in
all the three Se status i.e. deficient, adequate and excess
groups. In deficient groups (Ia and Ib) and in HCD fed
adequate group, Se level decreased significantly (p <
0.001), whereas in 1 ppm Se supplemented groups the
level increased significantly (p < 0.001) after 2 months in
comparison to 1-month data (Table 1).
Glutathione peroxidase activity
Glutathione peroxidase (GSH-Px) activity in liver
decreased significantly (p < 0.001) in Se deficiency (Ia and
Ib) and it increased on 1 ppm Se supplementation (IIIa
and IIIb) in comparison to respective adequate groups
(IIa and IIb). On HCD feeding significant increase (p <
0.001) was observed in all the groups in comparison to
respective controls. In Se deficient control group GSH-Px
level decreased, whereas in HCD supplemented Se defi-
cient and Se adequate as well as excess Se fed groups the
level increased significantly (p < 0.001) after 2 months as
compared to 1-month data (Table 1).
Total Cholesterol and LDL Level
In all the three Se status groups on HCD feeding signifi-
cant increase (p < 0.001) in total cholesterol and LDL-
cholesterol concentration was observed in comparison to
respective control groups. In Se deficient groups (Ia and
Ib) total cholesterol and LDL level increased and on 1
ppm Se supplementation it decreased significantly (p <
0.001) in comparison to respective adequate groups (IIa
and IIb). In both the Se deficient groups (Ia and Ib) and
in HCD fed adequate group lipid level increased signifi-
Table 1: Selenium levels in liver (µg/g) and serum (µg/L), GSH-Px levels in liver (µmoles of NADPH oxidized/min/mg protein) after 1 
and 2 months of control and high cholesterol diet (HCD) feeding.
Treatment 
period
Se deficient group Se adequate group Se excess group
Control Ia HCD Ib Control IIa HCD IIb Control IIIa HCD IIIb
Se in liver
1 month 1.83 ± 0.26DDD 1.20 ± 0.14***### 3.85 ± 0.29 3.11 ± 0.39** 4.57 ± 0.43LL 2.51 ± 0.29***B
2 months 1.23 ± 0.22DDDAA 0.73 ± 0.05***AAA### 3.97 ± 0.36 2.54 ± 0.27***A 6.51 ± 0.65AAALLL 4.38 ± 0.44***AAABBB
Se in serum
1 month 1.54 ± 0.15DDD 0.76 ± 0.04***### 2.51 ± 0.24 2.11 ± 0.27* 3.84 ± 0.34LLL 2.62 ± 0.27***BB
2 month 0.98 ± 0.07DDDAAA 0.51 ± 0.02***AAA### 2.82 ± 0.29 1.62 ± 0.17***AA 4.73 ± 0.39AALLL 3.58 ± 0.31***AAABBB
GSH-Px
1 month 281.45 ± 34.89DDD 354.19 ± 32.79**### 387.42 ± 25.86 467.19 ± 27.66*** 568.82 ± 52.94LLL 686.19 ± 50.58**BBB
2 month 160.33 ± 
22.78DDDAAA
463.73 ± 
39.91***AAA###
393.16 ± 49.67 593.28 ± 
35.38***AAA
672.91 ± 58.16AALLL 825.16 ± 
63.85**AABBB
Data is represented as mean ± SD from 6 observations.
*p<0.05, **p<0.01, ***p<0.001 represent comparison between control and HCD groups; Ap<0.05, AAp<0.01, AAAp<0.001 comparison between 1 
and 2 months; DDDp<0.001 comparison between group Ia and IIa; ###p<0.001 comparison between group Ib and IIb; LLp<0.01, LLLp<0.001 
comparison between group IIa and IIIa; Bp<0.05, BBp<0.01, BBBp<0.001 comparison between group IIb and IIIb.Lipids in Health and Disease 2005, 4:28 http://www.lipidworld.com/content/4/1/28
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cantly (p < 0.001), whereas it decreased on Se supplemen-
tation after 2 months in comparison to 1-month
treatment period (Table 2).
T3 and T4 levels
Levels of T3 decreased and T4 increased significantly (p <
0.001) on HCD feeding in comparison to respective con-
trols in all the three Se status groups. In Se deficiency (Ia
and Ib) T3 decreased and T4 level increased in comparison
to respective adequate groups, whereas on 1 ppm Se sup-
plementation T3 level increased and T4 level decreased sig-
nificantly (p < 0.001). In both the Se deficient groups and
in HCD fed adequate group (IIb) T3 decreased and T4
increased significantly and in Se supplemented groups T3
increased and T4 decreased after 2 months in comparison
to 1-month data (Fig. 1a &1b).
5'-DI activity and mRNA expression
5'-DI activity as well as mRNA expression in liver
decreased significantly (p < 0.001) on HCD feeding and
during Se deficiency in comparison to respective controls.
On 1 ppm Se supplementation, significant increase (p <
0.001) in enzyme activity and mRNA expression was
observed in comparison to adequate groups. In Se defi-
cient groups (Ia and Ib) and in HCD fed adequate group
the activity and mRNA expression decreased and it
increased significantly in 1 ppm Se supplemented groups
after 2 months in comparison to 1 month data (Fig. 1c
and Fig. 2a &2b).
LDL-R activity and mRNA expression
Percent remaining counts in blood after 120 h were
almost same in all the groups after one month, hence no
change was observed in LDL-R activity after one month of
diet feeding schedule (Fig. 3a &3b). However after 2
months, the percent remaining counts were higher in Se
deficient groups in comparison to adequate diet fed
groups, so the LDL-R activity decreased significantly (p <
0.001) in Se deficiency. On 1 ppm selenium supplemen-
tation LDL-R activity increased significantly in compari-
son to adequate groups. On HCD feeding the receptor
activity decreased significantly (p < 0.001) in all the three
selenium status groups. After 2 months receptor activity
decreased (p < 0.001) in Se deficient groups (Ia and Ib)
and in HCD fed adequate group, whereas it increased sig-
nificantly on 1 ppm selenium supplementation in com-
parison to 1 month treatment period (Fig. 4a &4b).
RT-PCR products of expected size i.e. 341 bp and 236 bp
were obtained for LDL-R and β-actin. mRNA expression
followed the same trend as it was observed for LDL-R
activity i.e. no significant change was observed in expres-
sion after 1 month of treatment period. But after 2 months
of diet feeding schedule mRNA expression decreased sig-
nificantly (p < 0.001) in Se deficiency (Ia and Ib) in com-
parison to adequate groups i.e. 31% and 68% decrease
was observed in groups Ia and Ib in comparison to IIa and
IIb respectively. On 1 ppm Se supplementation, signifi-
cant increase (p < 0.001) in RNA expression was observed
in comparison to adequate groups. On HCD feeding in all
the three selenium status groups significant decrease in
the expression was observed. In Se deficient groups (Ia
and Ib) and in HCD fed adequate group mRNA expres-
sion decreased and it increased significantly in 1 ppm Se
supplemented groups after 2 months in comparison to 1
month data (Fig. 5a &5b).
Apolipoprotein B levels
After one month of treatment, no significant change was
observed in apoB levels by ELISA (Table 2). However after
Table 2: Total cholesterol (mg/dl), LDL-cholesterol (mg/dl) and apolipoprotein B (A405) levels in serum after 1 and 2 months of control 
and high cholesterol diet (HCD) feeding schedule.
Treatment 
period
Se deficient group Se adequate group Se excess group
Control Ia HCD Ib Control IIa HCD IIb Control IIIa HCD IIIb
Cholesterol
1 month 107.87 ± 6.87DDD 246.54 ± 11.96##*** 83.62 ± 5.45 215.23 ± 13.45*** 74.43 ± 6.28L 184.29 ± 11.73***BB
2 months 120.23 ± 9.53DDDA 295.14 ± 13.43##***AAA 85.23 ± 5.24 269.82 ± 10.67***AAA 62.73 ± 5.38AALLL 165.34 ± 10.60***BBBA
LDL
1 month 41.47 ± 4.23DDD 94.82 ± 7.38#*** 32.16 ± 2.29 82.78 ± 7.17*** 28.62 ± 2.42L 70.88 ± 5.36***BB
2 months 48.35 ± 3.71ADDD 113.50 ± 9.16#***A 32.78 ± 2.75 99.73 ± 9.32***A 24.12 ± 2.06AALLL 60.59 ± 5.83***BBBAA
ApoB
1 month 0.195 ± 0.018 0.198 ± 0.019 0.191 ± 0.017 0.196 ± 0.016 0.189 ± 0.016 0.193 ± 0.018
2 months 0.287 ± 0.024DDDAAA 0.345 ± 0.028**AAA## 0.196 ± 0.016 0.275 ± 0.023***AAA 0.130 ± 0.011AAALLL 0.162 ± 0.015**AABBB
Data is represented as mean ± SD from 6 observations.
**p<0.01, ***p<0.001 represent comparison between control and HCD groups; Ap<0.05, AAp<0.01, AAAp<0.001 comparison between 1 and 2 
months; DDp<0.01, DDDp<0.001 comparison between group Ia and IIa; ##p<0.01, ###p<0.001 comparison between group Ib and IIb; Lp<0.05, 
LLp<0.01, LLLp<0.001 comparison between group IIa and IIIa; BBp<0.01, BBBp<0.001 comparison between group IIb and IIIb.Lipids in Health and Disease 2005, 4:28 http://www.lipidworld.com/content/4/1/28
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T3 (a), T4 (b) and 5'-DI (c) levels in serum in different groups: Ia-Se deficient control, Ib-Se deficient+HCD, IIa-Se adequate con- trol, IIb-Se adequate+HCD, IIIa-Se excess control, IIIb-Se excess+HCD after 1 and 2 months Figure 1
T3 (a), T4 (b) and 5'-DI (c) levels in serum in different groups: Ia-Se deficient control, Ib-Se deficient+HCD, IIa-Se adequate con-
trol, IIb-Se adequate+HCD, IIIa-Se excess control, IIIb-Se excess+HCD after 1 and 2 months. Data is represented as mean ± 
SD from 6 observations. **p<0.01, ***p<0.001 represent comparison between control and HCD groups; AAp<0.01, 
AAAp<0.001 comparison between 1 and 2 months; DDp<0.01, DDDp<0.001 comparison between group Ia and IIa; ##p<0.01, 
###p<0.001 comparison between group Ib and IIb; Lp<0.05, LLp<0.01, LLLp<0.001 comparison between group IIa and IIIa; 
BBp<0.01, BBBp<0.001 comparison between group IIb and IIIb.
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2 months apoB levels in liver increased significantly (p <
0.001) in Se deficient control and high cholesterol diet
(HCD) fed groups (Ia and Ib) in comparison to respective
adequate groups (IIa and IIb). Whereas the level signifi-
cantly (p < 0.001) decreased on 1 ppm Se supplementa-
tion in groups IIIa and IIIb. On HCD feeding a significant
increase (p < 0.001) in apoB level was observed in com-
parison to respective control groups in all the three Se sta-
tus groups after 2 months of diet feeding schedule. In
selenium deficient groups (Ia and Ib), and in selenium
adequate HCD fed group (IIb), the level increased and in
1 ppm selenium fed groups (IIIa and IIIb) it decreased sig-
nificantly after 2 months of respective diet feeding in com-
parison to 1-month treatment period (Table 2).
Apolipoprotein B expression by western blot followed the
similar trend as it was observed in ELISA. After one month
of treatment, no significant change in band intensity was
observed. So no change was there in apoB expression on
5'-DI mRNA analysis in liver in different groups: Ia-Se deficient control, IIa-Se adequate control, IIIa-Se excess control, Ib-Se  deficient+HCD, IIb-Se adequate+HCD, IIIb-Se excess+HCD after 1 and 2 months Figure 2
5'-DI mRNA analysis in liver in different groups: Ia-Se deficient control, IIa-Se adequate control, IIIa-Se excess control, Ib-Se 
deficient+HCD, IIb-Se adequate+HCD, IIIb-Se excess+HCD after 1 and 2 months. (a) mRNA expression by RT-PCR. (b) 
expression was quantified by densitometric analysis. β-actin was used as an internal control. Data is expressed as mean ± SD 
from 4 observations. *p<0.05, **p<0.01 represent comparison between control and HCD groups; Ap<0.05 comparison 
between 1 and 2 months; Dp<0.05, DDp<0.01 comparison between group Ia and IIa; ##p<0.01 comparison between group Ib 
and IIb; Lp<0.05, LLLp<0.001 comparison between group IIa and IIIa; Bp<0.05, BBBp<0.001 comparison between group IIb and 
IIIb.
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LDL-R activity in-vivo during selenium deficiency and on HCD feeding in different groups Figure 3
LDL-R activity in-vivo during selenium deficiency and on HCD feeding in different groups. (a) after 1 month of control diet feed-
ing. (b) after 1 month of HCD feeding. Radiolabelled LDL was injected to the rats, % decrease in counts in blood with time was 
taken as a measure of clearance of LDL from animal blood and in turn the LDL-R activity.
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high cholesterol diet feeding as well as in selenium defi-
ciency and on 1 ppm selenium supplementation (Fig. 6).
After 2 months, immunoblot band intensity was appar-
ently higher in Se deficient control and HCD fed groups
(Ia and Ib) in comparison to respective adequate diet fed
LDL-R activity in-vivo during selenium deficiency and on HCD feeding in different groups Figure 4
LDL-R activity in-vivo during selenium deficiency and on HCD feeding in different groups. (a) after 2 months of control diet 
feeding. (b) after 2 months of HCD feeding. Radiolabelled LDL was injected to the rats, % decrease in counts in blood with 
time was taken as a measure of clearance of LDL from animal blood and in turn the LDL-R activity.
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groups (IIa and IIb). Whereas the intensity was lower in 1
ppm Se supplemented groups IIIa and IIIb in comparison
to adequate groups IIa and IIb respectively. On choles-
terol supplemented diet feeding, apoB protein expression
was found to be increased in comparison to respective
control groups in all the three Se status groups after 2
months. In selenium deficient groups (Ia and Ib), and in
selenium adequate cholesterol fed group (IIb), apoB
expression increased and in 1 ppm selenium fed groups
(IIIa and IIIb), it decreased after 2 months of respective
diet feeding in comparison to 1-month treatment period
(Fig. 6)
Discussion
Various studies suggested the prospective role of selenium
in cardiovascular disorders [18]. Our results demonstrate
Hepatic LDL-R mRNA analysis in different groups: Ia-Se deficient control, IIa-Se adequate control, IIIa-Se excess control, Ib-Se  deficient+HCD, IIb-Se adequate+HCD, IIIb-Se excess+HCD after 1 and 2 months Figure 5
Hepatic LDL-R mRNA analysis in different groups: Ia-Se deficient control, IIa-Se adequate control, IIIa-Se excess control, Ib-Se 
deficient+HCD, IIb-Se adequate+HCD, IIIb-Se excess+HCD after 1 and 2 months. (a) mRNA expression by RT-PCR. β-actin 
was also amplified (house keeping gene). (b) bands were quantified by densitometric analysis. Data is expressed as mean ± SD 
from 4 observations. *p<0.05, **p<0.01, ***p<0.001 represent comparison between control and HCD groups; Ap<0.05, 
AAp<0.01, AAAp<0.001 comparison between 1 and 2 months; DDDp<0.001 comparison between group Ia and IIa; ###p<0.001 
comparison between group Ib and IIb; LLp<0.01, comparison between group IIa and IIIa; BBBp<0.001 comparison between group 
IIb and IIIb.
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that in selenium deficient animals significant increase in
total cholesterol and LDL-cholesterol level was observed
in comparison to adequate selenium fed animals [19].
Increased LDL is accumulatedin the intima, where it is
oxidized. This oxidized LDL is associated with increased
risk of coronary heart disease [20]. On 1 ppm Se supple-
mentation lipid levels decreased significantly [21], Se sup-
plementation might be protecting the LDL from oxidative
modifications and further atherogenic changes [22,23].
Further, selenium supplementation leads to an increase in
HDL cholesterol fraction [18]. HDL fraction increases the
cholesterol elimination from tissues including smooth
muscle cells in the aorta wall and facilitate the cholesterol
transport to the liver, thus preventing its deposition and
formation of atheromatous plaque [24].
In the present results in Se deficient groups, hepatic glu-
tathione peroxidase (GSH-Px) activity decreased signifi-
cantly in comparison to adequate groups (Table 1), so
these observations confirm the Se deficiency, which is
associated with decreased GSH-Px levels [25]. On high
cholesterol diet feeding GSH-Px activity increased in all
the groups. This increase in Se dependent GSH-Px on
HCD feeding is attributed to the increased lipoperoxida-
tive stress associated with cholesterol feeding as previ-
ously established in our lab [21]. Animals fed with the Se
deficient diet had decreased hepatic 5'-DI activity as well
as mRNA expression in comparison to the Se adequate
groups [16,17]. During selenium deficiency hepatic stores
of Se might be insufficient to allow the synthesis of 5'-DI.
On 1 ppm Se supplementation GSH-Px and 5'-DI levels
increased in control as well as HCD fed groups, this could
be due to the fact that being selenoproteins the level of
these two enzymes increased on Se supplementation.
Decreased level of T3 in selenium deficiency as well as on
HCD feeding might be owing to the decreased conversion
of T4 to T3 in the liver and other parts due to decreased 5'-
DI (selenoprotein) expression during Se depletion [17].
Present studies revealed that in Se deficiency the LDL-R
activity as well as mRNA expression is down regulated in
comparison to adequate Se diet fed animals after 2
months of diet feeding (Fig. 3 &4). This could be due to
the decreased T3 level during Se deficiency. T3 is directly
involved in the regulation of LDL-R expression via modu-
lation of SREBP-2 (sterol regulatory element-binding pro-
tein-2) gene expression. SREBP-2 is a major
transcriptional regulator of cholesterol uptake through
LDL-R [26]. In the present study we have observed that in
Se deficiency, cholesterol level increased, this increased
intracellular cholesterol level might be another reason to
down regulate the LDL-R expression through feedback sig-
naling pathway [27]. On feeding high cholesterol diet to
the animals, LDL-R activity and mRNA expression
decreased in all the three selenium status groups, so exog-
enous cholesterol given through diet is being used in the
signaling pathway and probably it is suppressing the tran-
scription of LDL-R through feedback mechanism. In case
of 1 ppm Se supplemented groups increased T3  level
might be upregulating the receptor expression.
In the current studies, on high cholesterol diet feeding for
2 months, apoB expression increased in all the three
groups (Table 2; Fig. 6). This increased level of apoB on
high cholesterol feeding is due to decreased expression of
LDL-R during hypercholesterolemia as observed in the
present studies. Decreased level of LDL-R is responsible
for decreased clearance of apoB along with LDL, so these
apolipoproteins are accumulated in the body [28,29].
During Se deficiency apoB levels in liver increased signifi-
cantly in the present studies [30]. This could be due to the
reason that selenium deficiency leads to decreased T3 lev-
els and inturn hypothyroid state through decreased
expression of 5'-DI enzyme [17,31], further hypothy-
roidism has been associated with increased level of apoB
[14]. As T3 is involved in LDL-R expression, so reduced T3
levels during selenium deficiency is responsible for
increase in apoB levels. Staels et al. [32] demonstrated that
thyroid hormones activate the LDL-R, leading to an
increased fractional catabolic rate of apoB without influ-
encing its synthesis rate. Davidson et al. [33] reported that
T3  administered to hypothyroid animals reduced the
plasma apoB concentrations.
In the present studies on 1 ppm selenium supplementa-
tion for 2 months decreased expression of apoB was
observed (Table 2; Fig. 6). This could be due to the
Western Blot analysis of apolipoprotein B Figure 6
Western Blot analysis of apolipoprotein B. Protein samples 
(30 µg) were resolved on 7.5% SDS-polyacrylamide electro-
phoresis and then electrophoretically transferred to PVDF 
membrane. Membrane was probed with antibody against 
apolipoprotein B. Lane1-Se deficient control; Lane2-Se ade-
quate control; Lane3-Se excess control; Lane4-Se defi-
cient+HCD; Lane5-Se adequate+HCD; Lane 6-Se 
excess+HCD. β-actin was used as an internal control.
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increased level of T3 observed in the present study on Se
supplementation through increased 5'-DI expression. So
it results in increased catabolic rate of apoB through
increased LDL-R expression. Davidson et al. [34] reported
the suppressed synthesis of apoB during T3 supplementa-
tion. Walton et al. [35] suggested the increased catabolism
of apoB through LDL receptors during hyperthyroidism. It
is probably a combination of suppressed apoB synthesis
and its increased elimination via LDL receptors during
selenium supplementation here, which is regulating the
apoB expression through T3 levels.
After one month of treatment, no significant change in the
LDL-R and apoB expression was observed, this might be
due to the reason that after 1 month the cholesterol accu-
mulation might not be up to the extent that it could stim-
ulate the feedback signaling pathway at translational as
well as at transcriptional level to regulate LDL-R expres-
sion. So apoB catabolism through LDL receptors was not
affected in different groups.
Conclusion
So, these results form the basis for a model that selenium
status in the body regulates apolipoprotein B expression
through selenoenzyme, 5'-DI. Selenium deficiency leads
to decreased expression of 5'-DI, decreased T3 levels and
decrease in LDL-cholesterol removal from blood through
downregulation of LDL-R mRNA expression, ultimately
decreased apoB catabolism through LDL receptors.
Whereas Se supplementation upto 1 ppm leads to
decreased apoB expression through increase in the LDL-R
mRNA expression again via modulation of 5' -DI expres-
sion and in turn has the protective role against hypercho-
lesterolemia. However, this interrelationship between
selenium status and apoB expression warrants further
investigation to decide the precise mechanism of lipid
metabolism through the effect of Se status on the apolipo-
protein B expression. Further studies must be undertaken
to explore the therapeutic role of selenium supplementa-
tion in hypercholesterolemia.
Methods
Experimental Animals
Young male Sprauge-Dawley rats (100 g-body weight)
were used in the present study. Animals were obtained
from the Central Animal House, Panjab University, Chan-
digarh.
Treatment Protocol
Animals were acclimatized to the laboratory animal room
and divided into three groups initially, group I (Se defi-
cient diet fed), group II (Se adequate diet fed) and group
III (Se excess diet fed). Feed and water were given ad libi-
tum. This Se diet was given to the animals initially for 10
days so as to achieve the required Se status. The animals in
these three groups were further divided into two each viz.:
Group Ia (Se deficient control), Group Ib (Se deficient +
high cholesterol diet fed); Group IIa (Se adequate con-
trol), Group IIb (Se adequate + high cholesterol diet fed);
Group IIIa (Se excess control), Group IIIb (Se excess +
high cholesterol diet fed). Treatment protocol was for 1
and 2 months.
Diet preparation
Yeast based synthetic Se deficient diet (supposed to con-
tain 0.02 ppm Se) was prepared in the laboratory itself
according to the composition given by Burk [36]. It con-
tained torula yeast (inactivated) 30%, sucrose 56.99%,
corn oil 6.67%, mineral mix 5%, vitamin mix 1%, dl-
methionine 0.3% and vitamin E 0.04%. Se adequate and
excess diet was prepared from Se deficient diet by supple-
menting it with 0.2 ppm and 1 ppm of Se as sodium
selenite (Sigma Chemicals). 2% of cholesterol (Loba-
Chemie, India) was added to the respective high choles-
terol diet (HCD) groups.
After completion of diet feeding schedule, rats were kept
on fasting for 10 hrs, anesthetized and exsanguinated.
Serum and tissue (liver) samples were collected from each
animal. Tissues were snap frozen in liquid nitrogen.
Serum total cholesterol and LDL-cholesterol levels were
estimated by enzymatic colorimetric kits obtained from E.
MERCK diagnostic (Germany). Various parameters were
carried out as detailed below
Selenium estimation
Selenium level was estimated by fluorimetric method
[37], based on the principle that Se content in serum or
tissue on acid digestion is converted to selenous acid. The
reaction between selenous acid and aromatic-o-diamines
such as 2,3-diamino-naphthalene (DAN) leads to the for-
mation of 4,5-benzopiazselenol, which displays brilliant
lime-green fluorescence when excited at 366 nm in
cyclohexane. Fluorescence emission in extracted cyclohex-
ane was read on fluorescence spectrophotometer using
366 nm as excitation wavelength and 520 nm as emission
wavelength.
Se-dependent GSH-Px activity
Glutathione peroxidase (GSH-Px) activity was assayed
using H2O2 as substrate [38]. The assay was carried out in
the post-mitochondrial fraction (PMF) of liver as already
published by us [39], the activity was expressed as µmoles
of NADPH oxidized/min/mg protein. Total protein was
done in all the samples [40].
T3 and T4 levels
Serum T3 and T4 estimation was done by radioimmu-
noassay (RIA) kits procured from BARC, Mumbai (Cat.
No. RIAK-4/4A and RIAK-5/5A for T3 and T4 respectively).Lipids in Health and Disease 2005, 4:28 http://www.lipidworld.com/content/4/1/28
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Type-I 5'-iodothyronine deiodinase activity
Type-I iodothyronine deiodinase (5'-DI) activity in liver
was estimated by following the method of Behne et al.
[41].
LDL-R activity
LDL-R activity was estimated in vivo by following the
method of Brown and Goldstein [42] and as per method-
ology already used by us [43]. Briefly, LDL isolated from
overnight fasting human plasma using a single vertical
spin density gradient ultra centrifugation [44], was radi-
olabeled with Na [131I] using chloramine-T [45]. Separa-
tion of labeled protein and unreacted iodide was done by
gel filtration through sephadex G-25 column. The steri-
lized radiolabeled LDL was injected to rats of different
groups. One ml of blood was taken 2 hrs after injection to
measure the counts of radiolabeled LDL, and considered
as counts at zero time interval or initial counts. Subse-
quently counts were also taken at 24, 48, 72, 96 and 120
hrs after injection. Percent decrease in counts at increasing
time interval was taken as a measure of clearance of LDL
from animal blood and in turn as indirect measurement
of the LDL-R activity.
Apolipoprotein B levels by ELISA
Apolipoprotein B concentration was estimated in liver by
ELISA using species specific (polyclonal anti rat apoB)
antibody (Santa Cruz Biotechnology, Inc. Santa Cruz,
CA). Optical density of each well was measured at 405 nm
in ELISA reader (Stat Fax; Awareness Technology Inc.,
USA).
mRNA analysis
The mRNA expression for 5'-DI andLDL-R was done in
liver using RT-PCR kit from QIAGEN.
RNA isolation
Total RNA from liver was extracted using TRI REAGENT
(Molecular Research Centre, Inc. Ohio). The integrity and
size distribution (quality) of RNA was examined by for-
maldehyde agarose gel electrophoresis.
RT-PCR
2 µg of total RNA template from different groups after
treatment with DNase I (Ambion) was used in RT-PCR
reaction. To the reaction mixture added 10 µl of 5X QIA-
GEN OneStep RT-PCR buffer (2.5 mM MgCl2 as final con-
centration), 2 µl of dNTP mix (10 mM of each dNTP), 5
µl of each forward and reverse gene specific primers (from
10 µM stock), 2 µl QIAGEN One Step RT-PCR Enzyme
Mix, 1 µl RNase inhibitor (1 U/µl) and finally 25 µl of
PCR grade RNase-free water (provided in the kit) to make
total volume 50 µl. Mixed it gently by vortex and centri-
fuged it to collect all the components at the bottom of the
PCR tubes. The PCR reaction was performed in the ther-
mal cycler (Techne Ltd. England) using following condi-
tions: the RT reaction was performed at 50°C for 50 min,
initial PCR activation was done at 95°C for 15 min, fol-
lowed by 35cycles of 94°C (denaturation) for 45 sec,
58.8°C (annealing) for 45 sec and 72°C (extension) for 1
min. Finally, incubated at 72°C for 10 min to extend any
incomplete single strands.
Optimal oligonucleotide primer pairs for RT-PCR were
selected with the aid of the software Gene Runner. The
primer sequence (5' to 3') for rat 5'-DI gene coding (+)
strand was TCTGGGATTTCATTCAAGGC, noncoding
strand was TAGAGCCTCTCAGGCAGAGC, LDL-R gene
coding (+) strand was ACCGCCATGAGGTACGTAAG,
noncoding (-) strand was GGGTCTGGACCCTTTCTCTC
and for rat β-actin gene coding (+) strand was
AGAGCTATGAGCTGCCTGAC, and the noncoding (-)
strand was CTGCATCCTGTCAGCCTACG. The length of
RT-PCR products for 5'-DI, LDL-R and β-actin were 346,
341 bp and 236 bp respectively.
Final PCR products were analyzed on 1.5% agarose gel
electrophoresis using 10 mM TE buffer. 5 µl of PCR prod-
uct was used from each tube. Densitometric analysis of
the bands was done by UviBandMap software (Uvitech,
England).
Western Immunoblot Analysis
Western immunoblot analysis for apoB was done in liver.
Tissue homogenate (10% w/v) from each group prepared
in 20 mM tris-HCl buffer (pH 7.4) at 4°C was centrifuged
at 3000 g for 10 min and the supernatant was used in the
assay. Protein sample (30 µg) from each treatment group
was separated by 7.5% SDS-polyacrylamide gel electro-
phoresis using minigel apparatus (BIORAD, UK). The sep-
arated proteins were electrophoretically transferred to
PVDF membrane (Immobilon-P, Millipore, USA). Mem-
brane was probed with antibody against apoB (Santa Cruz
Biotechnology Inc. Santa Cruz, CA). β-actin was used as
an internal control. Immunoblot analysis for β-actin was
also done by using antibody against β-actin (Oncogene,
USA).
Statistical analysis
Data is expressed as mean ± SD. Difference between differ-
ent groups was tested using student's t test for unpaired
values.
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